阿尔茨海默病;病理生理学基础和治疗干预综述。

PubMed ID
发表日期 2020年Sep月

原始出处 生命科学
Life sciences
作者 Abeysinghe  A A D T  Deshapriya  R D U S  Udawatte  C 

文献标题 阿尔茨海默病;病理生理学基础和治疗干预综述。
Alzheimer's disease; a review of the pathophysiological basis and therapeutic interventions.

文献摘要

阿尔茨海默病(AD)是一种神经退行性疾病,被认为是痴呆症最常见的病因。尽管巨大的全球经济负担和对患者近亲属的影响,但没有确切的治疗方法,因此需要改进治疗方法。虽然AD患者的记忆和认知功能受到严重影响,但确切的病因尚不清楚。β淀粉样斑块形成和聚集假说是解释疾病发病机制的著名假说之一。目前有五种食品和药物管理局(FDA)批准的药物作为治疗方案。这些药物都是用来对症治疗AD的,因此需要直接针对AD的病理改变进行疾病治疗。这种治疗方法可以基于抑制发病的关键步骤来设计。目前有新的AD候选药物具有不同的治疗机制,经历了不同的药物开发阶段。全球正在进行广泛的研究,以扩大对AD的确切机制的了解,并开发能够成功阻止疾病发生和发展的治疗药物。本文就如何理解AD提出了一种全面的认识方法,并提出了在AD治疗学发展中应考虑的建议。


Alzheimer's disease (AD) is a neurodegenerative disorder and is identified as the most common cause for dementia. Despite huge global economic burden and the impact on the close family of the patients, there is no definitive cure and thus, improved treatment methods are of need. While memory and cognition are severely affected in AD, exact etiology is yet unknown. The β-Amyloid plaque formation and aggregation hypothesis is among the well-known hypotheses used to explain disease pathogenesis. Currently there are five Food and Drug Administration (FDA) approved drugs as treatment options. All these drugs are used for symptomatic treatment of AD. Thus, disease modifying therapies which can directly address the pathological changes in AD, are needed. Such therapies could be designed based on inhibiting key steps of pathogenesis. Currently there are novel AD drug candidates with various therapeutic mechanisms, undergoing different stages of drug development. Extensive research is being done globally to broaden understanding of the exact mechanisms involved in AD and to develop therapeutic agents that can successfully hinder the occurrence and progression of the disease. In this review, a comprehensive approach to understanding AD and suggestions to be considered in the development of therapeutics for it are presented.


获取全文 10.1016/j.lfs.2020.117996